Mukaddes Avsar Saral1,2,3, Seref Bugra Tuncer1, Demet Akdeniz Odemis1, Ozge Sukruoglu Erdogan1, Seda Kilic Erciyas1, Pınar Saip4, Sevda Ozel5, Hulya Yazici6. 1. Division of Cancer Genetics, Department of Basic Oncology, Oncology Institute, Istanbul University, Fatih , 34093, Istanbul, Turkey. 2. Health Sciences Institute, Istanbul University, Beyazıt/Fatih, 34452, Istanbul, Turkey. 3. Health Services Vocational School of Higher Education, T.C. Istanbul Aydin University, Sefakoy Kucukcekmece, 34295, Istanbul, Turkey. 4. Department of Medical Oncology in Oncology Institute, Istanbul University, Fatih, 34093, Istanbul, Turkey. 5. Department of Biostatistics, Istanbul Faculty of Medicine, Istanbul University, Fatih, 34093, Istanbul, Turkey. 6. Division of Cancer Genetics, Department of Basic Oncology, Oncology Institute, Istanbul University, Fatih , 34093, Istanbul, Turkey. hulyayazici67@gmail.com.
Abstract
OBJECTIVES: Ovarian cancer is one of the most fatal gynecologic malignities. miR-16-5p, miR-17-5p, and miR-638 genes were found to have been associated with ovarian cancer in accordance with the data obtained from the previous microarray research performed by Tuncer et al. (J Ovarian Res 13(1):99, 2020). The expression levels of these miRNAs in the peripheral blood samples of 142 ovarian cancer patients, and 97 healthy controls were investigated for performing the validation, and to identify whether these genes were the possible biomarkers to be used in the early diagnosis of high-risk ovarian cancer patients, and in the prognosis of patients. METHODS: The miRNA expression analysis was performed using the miRNA-specific cDNA synthesis, and real-time PCR methods following the RNA isolation from the peripheral blood lymphocytes. RESULTS: miR-16-5p, miR-17-5p, and miR-638 miRNA gene expression levels were found to have twofold higher expression levels in patient groups compared with the gene expression levels in healthy controls, and were statistically significant (p < 0.05). In addition, the comparison of the miRNA expression levels with the clinical data of patients showed that there was a significant difference with smoking history and the increased expression level of miR-17-5 (p: 0.007). There was a significant difference between the increased expression level of miR-638 with the locally advanced stage, and abdominal/pelvic metastatic patients (p: 0.03). CONCLUSIONS: The obtained data suggest that miR-16-5p, miR-17-5p, and miR-638 molecules might be the noninvasive biomarkers in identifying the ovarian cancer. However, the investigation and monitoring of the changeability of these biomarkers in benign ovarian diseases, and during the treatment must be performed in future studies for identifying the accurate diagnostic, and prognostic features of miRNAs.
OBJECTIVES: Ovarian cancer is one of the most fatal gynecologic malignities. miR-16-5p, miR-17-5p, and miR-638 genes were found to have been associated with ovarian cancer in accordance with the data obtained from the previous microarray research performed by Tuncer et al. (J Ovarian Res 13(1):99, 2020). The expression levels of these miRNAs in the peripheral blood samples of 142 ovarian cancer patients, and 97 healthy controls were investigated for performing the validation, and to identify whether these genes were the possible biomarkers to be used in the early diagnosis of high-risk ovarian cancer patients, and in the prognosis of patients. METHODS: The miRNA expression analysis was performed using the miRNA-specific cDNA synthesis, and real-time PCR methods following the RNA isolation from the peripheral blood lymphocytes. RESULTS: miR-16-5p, miR-17-5p, and miR-638 miRNA gene expression levels were found to have twofold higher expression levels in patient groups compared with the gene expression levels in healthy controls, and were statistically significant (p < 0.05). In addition, the comparison of the miRNA expression levels with the clinical data of patients showed that there was a significant difference with smoking history and the increased expression level of miR-17-5 (p: 0.007). There was a significant difference between the increased expression level of miR-638 with the locally advanced stage, and abdominal/pelvic metastatic patients (p: 0.03). CONCLUSIONS: The obtained data suggest that miR-16-5p, miR-17-5p, and miR-638 molecules might be the noninvasive biomarkers in identifying the ovarian cancer. However, the investigation and monitoring of the changeability of these biomarkers in benign ovarian diseases, and during the treatment must be performed in future studies for identifying the accurate diagnostic, and prognostic features of miRNAs.
Authors: Fariba Salehi; Lesley Dunfield; Karen P Phillips; Daniel Krewski; Barbara C Vanderhyden Journal: J Toxicol Environ Health B Crit Rev Date: 2008-03 Impact factor: 6.393
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Patrick H D Petersen; Joanna Lopacinska-Jørgensen; Douglas V N P Oliveira; Claus K Høgdall; Estrid V Høgdall Journal: In Vivo Date: 2022 Jul-Aug Impact factor: 2.406